Cargando…

Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates

Along with cognitive decline, 90% of patients with dementia experience behavioral and psychological symptoms of dementia, such as psychosis, aggression, agitation, and depression. Atypical antipsychotics are commonly prescribed off-label to manage certain symptoms, despite warnings from the regulato...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marcinkowska, Monika, Śniecikowska, Joanna, Fajkis, Nikola, Paśko, Paweł, Franczyk, Weronika, Kołaczkowski, Marcin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048860/ https://www.ncbi.nlm.nih.gov/pubmed/32052375 http://dx.doi.org/10.1007/s40263-020-00707-7

Ejemplares similares

Study on a Three-Step Rapid Assembly of Zolpidem and Its Fluorinated Analogues Employing Microwave-Assisted Chemistry
por: Fajkis, Nikola, et al.
Publicado: (2020)

Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia
por: Marcinkowska, Monika, et al.
Publicado: (2021)

Idalopirdine, a selective 5-HT(6) receptor antagonist, reduces food intake and body weight in a model of excessive eating
por: Kotańska, Magdalena, et al.
Publicado: (2018)

2-(4-Fluorophenyl)-1H-benzo[d]imidazole as a Promising Template for the Development of Metabolically Robust, α1β2γ2GABA-A Receptor-Positive Allosteric Modulators
por: Marcinkowska, Monika, et al.
Publicado: (2023)

Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia
por: Davies, Simon JC, et al.
Publicado: (2018)

Synthesis and biological evaluation of N-arylpiperazine derivatives of 4,4-dimethylisoquinoline-1,3(2H,4H)-dione as potential antiplatelet agents
por: Marcinkowska, Monika, et al.
Publicado: (2018)

Voxel-Based Morphometry Correlates of an Agitated-Aggressive Syndrome in the At-Risk Mental State for Psychosis and First Episode Psychosis
por: Huber, Christian G., et al.
Publicado: (2018)

REJECTION OF CARE, AGGRESSION, AND AGITATION IN PERSONS WITH DEMENTIA: A REVIEW OF DEFINITIONS IN DEMENTIA MEASURES
por: Choi, Scott, et al.
Publicado: (2019)

Metabolic and Cardiovascular Benefits and Risks of EMD386088—A 5-HT(6) Receptor Partial Agonist and Dopamine Transporter Inhibitor
por: Kotańska, Magdalena, et al.
Publicado: (2017)

Acute interventions for aggression and agitation in psychosis: study protocol for a systematic review and network meta-analysis
por: Ostinelli, Edoardo G, et al.
Publicado: (2019)

The selective 5-HT(1A) receptor biased agonists, F15599 and F13714, show antidepressant-like properties after a single administration in the mouse model of unpredictable chronic mild stress
por: Głuch-Lutwin, Monika, et al.
Publicado: (2021)

Managing acute agitation and aggression in the world of drug shortages
por: Miller, Jennifer
Publicado: (2021)

Developing an ontology for representing the domain knowledge specific to non‐pharmacological treatment for agitation in dementia
por: Zhang, Zhenyu, et al.
Publicado: (2020)

Management of Agitation in Behaviours That Challenge in Dementia Care: Multidisciplinary Perspectives on Non-Pharmacological Strategies
por: James, Ian Andrew, et al.
Publicado: (2023)

Idalopirdine – a small molecule antagonist of 5-HT(6) with therapeutic potential against obesity
por: Dudek, Magdalena, et al.
Publicado: (2015)

Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses
por: Wiesner, Agnieszka, et al.
Publicado: (2022)

Discomfort and agitation in older adults with dementia
por: Pelletier, Isabelle Chantale, et al.
Publicado: (2007)

Dementia-related agitation: a review of non-pharmacological interventions and analysis of risks and benefits of pharmacotherapy
por: Ijaopo, E O
Publicado: (2017)

The Interactive Relationship between Pain, Psychosis, and Agitation in People with Dementia: Results from a Cluster-Randomised Clinical Trial
por: Habiger, Torstein F., et al.
Publicado: (2016)

Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses
por: Nirogi, Ramakrishna, et al.
Publicado: (2022)

Gabapentin in the treatment of dementia-associated nocturnal agitation
por: Buskova, Jitka, et al.
Publicado: (2011)

Stress Cardiomyopathy in Association with Severe Agitation in Dementia
por: Amin, Hina, et al.
Publicado: (2019)

ELECTROCONVULSIVE THERAPY FOR AGITATION IN LEWY BODIES DEMENTIA
por: Echeverria, C., et al.
Publicado: (2023)

New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin
por: Caraci, Filippo, et al.
Publicado: (2020)

Agitation and aggression in people living with dementia and mild cognitive impairment in shared-housing arrangements – validation of a German version of the Cohen-Mansfield Agitation Inventory-Short Form (CMAI-SF)
por: Kratzer, André, et al.
Publicado: (2023)

Memantine treats psychosis and agitation associated with Moderna COVID-19 vaccine
por: Siao, Wen-Huei, et al.
Publicado: (2023)

A descriptive analysis of pharmacological management of aggression and/or agitation in patients with traumatic brain injury in a Southwest Virginia inpatient population
por: Rahmani, Elham, et al.
Publicado: (2022)

Effects of Music on Agitation in Dementia: A Meta-Analysis
por: Pedersen, Siv K. A., et al.
Publicado: (2017)

Evidence for using dextromethorphan-quinidine for the treatment of agitation in dementia
por: Tampi, Rajesh R, et al.
Publicado: (2020)

Management of Agitation in Dementia and Effects on Inpatient Length of Stay
por: Silverstone-Simard, Isabelle, et al.
Publicado: (2021)

Challenges of Agitation in Dementia: A Plea for Early Discussion
por: Richler, Leah G., et al.
Publicado: (2023)

A reflection on the use of Antidepressants to manage agitation in dementia
por: Basto, M.D.R.D.R.F.D., et al.
Publicado: (2022)

The outcomes of a person-centered, non-pharmacological intervention in reducing agitation in residents with dementia in Australian rural nursing homes
por: Isaac, Vivian, et al.
Publicado: (2021)

Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α(2)-adrenoceptor and trace amine-associated receptor 1 ligand
por: Kotańska, Magdalena, et al.
Publicado: (2023)

Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia
por: Kołaczkowski, Marcin, et al.
Publicado: (2014)

Agitation in Dementia: Relation to Core Cerebrospinal Fluid Biomarker Levels
por: Bloniecki, Victor, et al.
Publicado: (2014)

Measuring Electrodermal Activity to Improve the Identification of Agitation in Individuals with Dementia
por: Melander, Catharina, et al.
Publicado: (2017)

Agitation near the end of life with dementia: An ethnographic study of care
por: Sampson, Elizabeth L., et al.
Publicado: (2019)

Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions
por: Carrarini, Claudia, et al.
Publicado: (2021)

The Impact of Agitation in Dementia on Caregivers: A Real-World Survey
por: Schein, Jeff, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0gc3c5v4cag6fpq9reqhvert4r